ASX Announcement **17 March 2021**

Atomo to present at NWR Virtual Investor Conference

SYDNEY Australia Wednesday, 17 March 2021 – Australian rapid blood test company Atomo Diagnostics Limited (ASX: AT1) (**Atomo**) is pleased to announce it will present at the NWR Virtual Investor Conference to be held on Thursday, 18 March 2021.

The Company invites shareholders and investors to see Atomo Diagnostics CEO John Kelly and CFO Will Souter present an update at 12:30pm (AEDT) on 18 March 2021.

Event: NWR Virtual Investor Conference
Presenting: Mr John Kelly (CEO, Atomo Diagnostics) and Mr Will Souter (CFO, Atomo Diagnostics)
Time: Thursday, 18 March 2021, 12:30pm (AEDT) for 25 minutes

Investors are invited to submit questions prior to the event to:
simon@nwrcommunications.com.au

Investors can register online to view the presentation here:
https://us02web.zoom.us/webinar/register/WN_vWcRVTYnT1qtWEXW-7O1GA

For further information on the conference click here: https://nwrconference.webflow.io/

For more information, please contact:

Jane Lowe
IR Department
jane.lowe@irdepartment.com.au
Phone: +61 411 117 774

John Kelly
Atomo Diagnostics
john.kelly@atomodiagnostics.com
Phone: +61 401 922 279

This announcement was authorised by John Kelly, Managing Director.

About Atomo

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo's patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. The Company has supply agreements in place for tests targeting infectious diseases including COVID-19, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com.